The
report analyzes and presents an overview of " Glaucoma - 5EU
Drug Forecast and Market Analysis to 2023 ” worldwide.
Glaucoma
is a leading cause of preventable blindness globally. This chronic
progressive optic neuropathy causes irreversible vision loss through
damage to the optic nerve. There are currently no treatments that can
directly prevent this damage, and all commercially available glaucoma
therapies focus on lowering elevated intraocular pressure (IOP), a
known risk factor for glaucoma development and progression. The
launch of fixed-dose combination (FDC) products, which combine drugs
from these various classes, will continue to be a source of
significant growth in this market. The glaucoma market is about to
enter a phase of new growth with the arrival of first-in-class drugs,
such as Aeries Rhopressa, Bausch & Lombs Vesneo (latanoprost
bunod), and Inoteks trabodenoson into the 7MM during the forecast
period, which will generate additional growth in the global glaucoma
market.
GlobalData
estimates that drug sales for glaucoma in the 5EU reached $250m
during the base year of 2013. After an initial period of minimal
growth, GlobalData anticipates a moderate and steady growth trend
from 2015 onwards. This can be partially attributed to the expected
arrival of the recently approved FDC products Simbrinza and Taptiqom
during 2015, and to the expected launch of five pipeline products
during the forecast period.
Download
Sample copy of this Report @
Scope
-
Overview of Glaucoma including epidemiology, etiology, symptoms,
diagnosis, pathology and treatment guidelines as well as an overview
on the competitive landscape.
-
Detailed information on the key drugs in 5EU including product
description, safety and efficacy profiles as well as a SWOT analysis.
-
Sales forecast for the top drugs in 5EU from 2013-2023.
-
Analysis of the impact of key events as well the drivers and
restraints affecting 5EU Glaucoma market.
Reasons
to buy
-
Understand and capitalize by identifying products that are most
likely to ensure a robust return
-
Stay ahead of the competition by understanding the changing
competitive landscape for Glaucoma.
-
Effectively plan your M&A and partnership strategies by
identifying drugs with the most promising sales potential
-
Make more informed business decisions from insightful and in-depth
analysis of drug performance
-
Obtain sales forecast for drugs from 2013-2023 in 5EU.
Table
of Content :
1
Table of Contents 2
1.1
List of Tables 6
1.2
List of Figures 9
2
Introduction 10
2.1
Catalyst 10
2.2
Related Reports 10
3
Disease Overview 12
3.1
Etiology and Pathophysiology 14
3.1.1
Etiology 14
3.1.2
Pathophysiology 17
3.2
Classification 20
3.3
Symptoms 21
3.4
Diagnosis 22
4
Disease Management 27
4.1
Diagnosis and Treatment Overview 27
4.1.1
Diagnosis 27
4.1.2
Treatment Guidelines 28
4.1.3
Leading Prescribed Drugs 30
4.1.4
Clinical Practice 30
4.2
5EU 32
5
Competitive Assessment 38
5.1
Overview 38
5.2
Product Profiles - Main Brands and Drug Classes 40
5.2.1
Xalatan (latanoprost) 40
5.2.2
Lumigan (bimatoprost) 46
5.2.3
Travatan (travoprost) 50
5.2.4
Tapros (tafluprost) 54
5.2.5
Beta Blockers 61
5.2.6
Carbonic Anhydrase Inhibitors 66
5.2.7
Alpha-Adrenergic Agonists 70
5.2.8
Simbrinza (brinzolamide + brimonidine) 73
5.2.9
Glanatec (ripasudil hydrochloride hydrate) 76
6
Unmet Need and Opportunity 82
6.1
Overview 82
6.2
Simplified Dosing Regimen 86
6.2.1
Unmet Need 86
6.2.2
Gap Analysis 87
6.2.3
Opportunity 90
6.3
Reminder Systems 91
6.3.1
Unmet Need 91
6.3.2
Gap Analysis 91
6.3.3
Opportunity 92
Follow
us on LinkedIn:
https://www.linkedin.com/company/marketresearchreports-biz
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
us:
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-618-1030
USA:
Canada Toll Free: 866-997-4948
No comments:
Post a Comment